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Purpose.T oe x p l o r et h ee ﬀects of cucurbitacin B on the radiation survival of human breast cancer cells and to elucidate the cellular
mechanism of radiosensitization if any. Materials and Methods. Human breast carcinoma cell lines were treated with cucurbitacin
B before irradiation with 0–10Gy of 137Cs gamma rays. The eﬀect of cucurbitacin B on cell-survival following irradiation was
evaluated by colony-forming assay. Cell cycle distributions were investigated using ﬂow cytometry. Real-time PCR and western
blots were performed to investigate the expression of cell cycle checkpoints. Results. Cucurbitacin B inhibited breast cancer cell
proliferation in a dose-dependent manner. Only MDA-MB-231 and MCF7:5C cells but not SKBR-3 cells were radiosensitized by
cucurbitacin B. Flow cytometric analysis for DNA content indicated that cucurbitacin B resulted in G2/M arrest in MDA-MB-231
and MCF7:5C but not SKBR-3 cells. Moreover, Real-time PCR and western blot analysis demonstrated upregulated p21 expression
beforeirradiation,alikelycauseofthecellcyclearrest.Conclusion.Takentogether,theseﬁndingssuggestthatcucurbitacinBcauses
radiosensitizationofsomebreastcancercells,andthatcucurbitacinBinducedG2/Marrestisanimportantmechanism.Therefore,
combinations of cucurbitacin B with radiotherapy may be appropriate for experimental breast cancer treatment.
1.Introduction
Breast cancer is now the most common cause of female
cancer and leading cause of cancer deaths among women
in the United States and many other parts of the world
[1, 2]. Over the past several decades, the incidence of
breast cancer has been increasing in economically developed
countries [3]. Human epidermal growth factor receptor 2
(Her2) and Estrogen receptor (ER) play critical roles in
the development and progression of breast cancer. About
80% of breast cancers are hormone-receptors positive and
express estrogen receptors [4]. About 20% of breast cancers
do not express estrogen receptor and also Her2 [5, 6].
Therefore, breast cancer that negative for ER and Her2 does
not respond to hormonal therapy. Current therapies for the
treatment of breast cancer may result in drug resistance or
toxicity. There is growing interest in the use of herbs to
aid in the maintenance of women’s health; it is interesting
to use of herbs for the women’s health care. Plants contain
a wide variety of chemicals that have potent biological
eﬀects, including anticancer activity. Natural cucurbitacins
are highly oxygenated, tetracyclic triterpenes containing the
cucurbitane nucleus skeleton and are predominantly found
inplantsofthefamilycucurbitaceae,membersofwhichhave
long been used in oriental medicines because of the wide
rangebiologicalactivitytheyexhibitedinplantsandanimals.
Among the various cucurbitacins, the most abundant is
cucurbitacin B. Cucurbitacin B (Scheme 1)e x t r a c t e df r o m
the Thai herb Trichosanthes cucumerina L. has been shown
to have anticancer, antimicrobial, and anti-inﬂammatory
activities [7, 8]. Several studies reported that cucurbitacin
B and its relatives inhibit the growth of human malignant
cells both in vitro and in vivo including breast cancer [9],
head and neck squamous cell carcinoma [10], pancreatic2 Journal of Oncology
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Scheme 1: Structure of cucurbitacin B.
cancer [11], hepatocellular carcinoma [12], osteosarcoma
[13], and myeloid leukemia [14]. Our previous report
has shown that cucurbitacin B exerts anticancer eﬀect by
inhibiting telomerase via downregulating both the hTERT
and c-Myc expression and arrest of the cell cycle at G2/M
phase in breast cancer cells [15]. Some studies have reported
that cells are most sensitive to radiation in G2/M and
most resistant in S phase [16]. For example, synchronized
Chinese hamster cells were most sensitive to irradiation
during mitosis and in G2 phase and less sensitive in G1
and the latter past of S phase [17, 18]. Drugs, including
Docetaxel, that arrest cells cell in G2/ Mp h a s eo fc e l lc y c l e
have been demonstrated as radiosensitizer agent [19]. The
aims of this study were to determine the radiosensitizing
potential of cucurbitacin B in human breast cancer cells and
to elucidate the cellular mechanism of the radiosensitization.
In the present study, we demonstrated that cucurbitacin
B sensitizes human breast cancer cells to radiation by
inducing them to accumulate in G2/M phase of the cell
cycle.
2.MaterialsandMethods
2.1.CellLinesandDrugTreatment. Humanbreastcancercell
lines(SKBR−3(ER −/Her2+),MDA-MB-231(ER−/Her2−),
and hormone-independent MCF7:5C (ER−/Her2−)) was
cultured at 37◦Cu n d e ra5 %C O 2 atmosphere. SKBR-3
breast cancer cells were maintained in McCoy’s 5A medium.
MDA-MB-231 and MCF7:5C were maintained in DMEM/
F12 medium. All medium were supplemented with 10% fetal
bovine serum and 1% penicillin/streptomycin.
2.2. Drug and Radiation Treatment. Cucurbitacin B was
authenticated by Professor Dr. Apichart suksamrarn from
Faculty of Science, Ramkhamhaeng University, Bangkok,
Thailand.Thiscompoundwasdissolvedin10%dimethylsul-
foxide (DMSO) and diluted with DMEM/F12 medium and
McCoy’s 5A medium to the desired concentrations prior to
use. A cesium machine was used to radiate cells with a dose
ranging from 0 to 10Gy.
2.3. Clonogenic Survival Assay. Cells were seeded in a 100-
mm culture plate and treated with the indicated concentra-
tion of cucurbitacin B for 48hr prior to radiation exposure.
After exposure, cells were then trypsinized and seed on the
basis of diﬀerence density in a 60mm culture plate with
5m Lo fm e d i u m .T h ep l a t e sw e r ei n c u b a t e da t3 7 ◦Cu n d e r
a5 %C O 2 atmosphere for 14–21 day. The cells were ﬁxed in
ethanol and stained with crystal violet. Colonies containing
more than 50 cells were counted as survivors. Surviving
fractions were calculated by normalization to the plating
eﬃciency of appropriate control groups.
2.4. Cell Cycle Analysis. For cell cycle analysis, cells were
treated with cucurbitacin B at various concentrations for
48hr and harvested. The cells were trypsinized and resus-
pend in 1mL DPBS. One million cells were centrifuged and
suspended in 0.5mL of Krishan reagent (0.1% Na citrate,
0.03% NP-40, 0.05mg/mL PI, 0.02mg/mL RNase A) before
analysis.ThestainedcellsweresubjectedtoDNAcontent/cell
cycle analysis using an LSR ﬂow cytometer.
2.5. Apoptosis Analysis. For apoptosis, the Annexin V-FITC
Apoptosis Detection Kit (BD bioscience, Bedford, MA)
was used to assess annexin V-positive cells. Brieﬂy, fresh
cell preparations were incubated with 1x annexin binding
buﬀerandannexinV-FITC-(2.5μg/mL)conjugatedprimary
antibody for 15min on ice. After incubation, propidium
iodide (PI; 10μg/mL) was added to the suspension and the
cells were analyzed by ﬂow cytometry using an LSR ﬂow
cytometer.
2.6. Quantiﬁcation of p21 mRNA. Cells (5 × 105 cells/well)
were seeded into 6-well plate and treated with various
concentration of cucurbitacin B for 48hr. Total RNA was
isolated from each cell line using the Qiagen RNeasy
Mini Kit (Qiagen, Valencia, CA). Two micrograms of
total RNA were reverse-transcribed with random primer
according to the manufacture’s protocol using High-
Capacity cDNA Reverse Transcription kit (Applied Biosys-
tems, Foster City, CA). Real-time PCR was performed
using Fast SYBR Green Master Mix (Applied Biosystems)
with the Applied Biosystems 7500 Fast Real-Time PCR
system (Applied Biosystems). The PCR primers set were
asfollows:sense5 -TGAGCCGCGACTGTGATG-3  andanti-
sense5 -GTCTCGGTGACAAAGTCGAAGTT-3  for p21 and
sense5 -GAAGGTGAAGGTCGGAGTC-3  and anti-sense5 -
GAAGATGGTGATGGGATTTC-3  for GAPDH. The rela-
tive ratio of p21 was then calculated using the formula:
2−ΔΔCt = 2−{ΔCt(Cucurbitacin B-treated)−ΔCt(untreated)},w h e r eΔCt =
Ct(p21)−Ct(GAPDH).
2.7. Western Blot Analysis. After cucurbitacin B treatment,
cell pellets were collected and lysed with 100μLR I P A
cell-lysis buﬀe r( 5 0 m MT r i sp H8 . 0 ,1 5 0 m MN a C l ,0 . 1 %
SDS, 0.5% Na Deoxycholate, 1% TX-100) plus 1mM NaF,
10mM NaVO4, 10mM PMSF, and 1/100 protease inhibitor
cocktail (Sigma). Total protein was determined using Bio-
Radproteinassay(Lifescience,Hercules,CA).EqualamountJournal of Oncology 3
of proteins were separated by 12.5% SDS-Polyacrylamide
gels and electrotransferred onto nitrocellulose membranes
and treated with anti p21 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) overnight. Equal protein loading was
conﬁrmed on all immunoblots using beta-tubulin antibody
(Developmental Studies Hybridoma Bank, University of
Iowa, Iowa City, IA) at a dilution 500. Goat anti-rabbit IgG
(BD Transduction Laboratories, San Diego, CA) was used as
a secondary antibody against all primary antibodies. Bands
werevisualizedbychemiluminescencewithECLplusreagent
(Pierce, Rockford, IL) on a Typhoon FLA 7000.
2.8. Statistical Analysis. All experiments were performed at
least three times. Statistical analysis was performed using
one-way ANOVA to compare the eﬀect among control
(without cucurbitacin) and treated cells. P value < 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Cucurbitacin B Induced Clonogenic Inhibition of Breast
Cancer Cells. The inhibitory eﬀect of cucurbitacin B on
colony formation in human breast cancer cells was evaluated
by clonogenic assay. Cells were incubated with cucurbitacin
B alone for 48hr and then allowed to form colonies in
fresh medium. The surviving fraction as a function of drug
concentration is shown in Figure 1. The average 50% (IC50)
inhibitory concentrations for clonogenic cell death in three
cells was 3.2, 2.4, and 1.9μM for MCF7:5C, and MDA-MB-
231, and SKBR-3 respectively. The results are the average
from three independent experiments for each cell lines. In
the clonogenic assay SKBR-3, was the most sensitive cell to
cucurbitacin B under the same condition for other cells.
3.2. Cell Cycle. Eﬀect of cucurbitacin B on cell cycle pro-
gression in MCF7:5C, MDA-MB-231, and SKBR-3 cells were
analyzed according to the principle of the DNA content in
each phase of, cell cycle. Cells were treated with cucurbitacin
B for 48hr, and DNA content was analyzed via ﬂow
cytometry. MCF7:5C and MDA-MB-231 cells after treated
were arrested at G2/M phase of cell cycle with a decrease
of cells population in G1 and S phase of cell cycle, as was
observed in several cancer cell lines. However, in contrast to
the eﬀect of cucurbitacin B on MCF7:5C and MDA-MB-231
cells, cucurbitacin B did not contribute to G2/M phase arrest
in SKBR-3 cells (Figure 2).
3.3. Apoptosis Eﬀe c to fC u c u r b i t a c i nBo nB r e a s tC a n c e r
Cells. Apoptosis eﬀect of cucurbitacin B was evaluated by
using Annexin V-FITC and propidium iodide staining. This
assay revealed that the negatively charged phospholipids
phosphatidylserine found on the interior surface of the
plasma membrane of the cells is trans-located to the cell
surface during apoptosis. After 48hr incubation with 0μM,
2.5μM, and 5μM of cucurbitacin B, cells were stained and
subjected to bivariate ﬂow cytometric analysis. As shown
in Figure 3, untreated cells did not show any signiﬁcant
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Figure 1: The inhibitory eﬀects of cucurbitacin B on colony forma-
tion in breast cancer cells. MCF7:5C, MDA-MB-231, and SKBR-3
were treated with the indicated concentration of cucurbitacin B for
48hr. After incubating, cells were seeded on the basis of diﬀerence
density in a 60mm culture plate with 5mL of fresh medium. At
14 days after seeding, colonies were ﬁxed and stained with 0.1%
crystal violet. Results shown are the average of three independent
experiments.
∗P < 0.05 versus nontreated control,
∗∗P < 0.01
versus nontreated control.
apoptosis, whereas cells become apoptotic with cucurbitacin
B treatment at the indicated concentration in all cells.
3.3.1. p21 mRNA Expression. To determine the eﬀect of
cucurbitacin B on p21 mRNA expression, all three cell lines
were incubated with cucurbitacin B for 48hr, in parallel
with untreated cell. Exposure of MCF7:5C, MDA-MB-231,
a n dS K B R - 3c e l ll i n e st o2 . 5μMa n d5μM of cucurbitacin B
resulted in the progressive increase p21 mRNA level. SKBR-
3 shows the highest induction of p21 mRNA expression
after cucurbitacin B treatment. The expression p21 mRNA
in SKBR-3 was increased up to 20 times when compared
with untreated cell while MCF7:5C and MDA-MB-231 was
increased 3-4 times as shown in Figure 4(a). The real-time
PCR products were applied on 0.8% agarose gel containing
ethidium bromide (EtBr) to scrutinize that the PCR reaction
was speciﬁc and that cucurbitacin B induced gene expression
of p21.
3.3.2. Upregulation of p21 Protein by Cucurbitacin B. We
examined the eﬀect of cucurbitacin B on the expression
of cell cycle regulated protein by western blot analysis.
Cells were incubated with the indicated concentration of
cucurbitacin B for 48hr and total protein were extracted
for western blot analysis. As shown in Figure 5,p r o t e i n
expression of cyclin-dependent kinase inhibitor p21 was
signiﬁcantly increased following cucurbitacin B treatment in
allstudycells.SKBR-3cells,whichshowedthehighestmRNA
accumulation in response to cucurbitacin B, also showed the
greatest induction of the p21 protein; however, this was not4 Journal of Oncology
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Figure 2: Eﬀect of cucurbitacin B on the cell cycle progression of breast cancer cells. MCF7:5C, MDA-MB-231, and SKBR-3 were treated
with cucurbitacin B for 48hr, and then stained with propidium iodide (PI) and subjected to ﬂow cytometric analysis. The DNA histograms
shown are representative of three independent experiments. Blockage at G2/M and apoptotic induction was observed (SubG1).
necessarily linked to G2/M arrest or radiation sensitization
by cucurbitacin B.
3.4. The Radiopotentiating Eﬀect of CuB on Breast Can-
cer Cells. To determine whether cucurbitacin B sensitized
human breast cancer cells to ionizing radiation, all three
cell lines were treated with 5μM cucurbitacin B for 48hr
following irradiation with a 137Cs gamma-irradiator at doses
ranging 0–8Gy. The cells were then allowed to form colonies
in fresh medium. The plating eﬃciency of all cells was
between 60 and 80%. Figure 6 shows the radiation survival
curves derived from clonogenic assays of the three cell lines
irradiated after 48hr incubation with cucurbitacin B. The
latter slope of survival curve of MCF7:C and MDA-MB-231
cells for radiation and cucurbitacin B treated were greater
than radiation only, especially at the 6 and 8Gy radiation
doses, indicating that cucurbitacin B treatment augmented
the eﬀects of radiation in both cell lines where G2/M arrest
was observed to occur. However, SKBR-3 did not show to
augmenttheeﬀectsofradiation,consistentwiththecellcycle
distribution shown in Figure 2 and the absence of a G2/M
arrest in SKBR-3 cells.
4. Discussion
The Cucurbitacins are highly oxygenated, tetracyclic triter-
penes containing the cucurbitane nucleus skeleton and
are of great interest because of the wide range biological
activity they exhibited in plants and animals. Cucurbitacins
have been reported to inhibit several types of cancers.
Cucurbitacinsaredividedintotwelvecategories[20].Among
the various cucurbitacins, the most abundant is cucurbitacin
B[ 21]. Many reports have shown that cucurbitacin B has
potent antiproliferative eﬀect on breast cancer cells. For
instance, cucurbitacin B, extracted from root and fruit juice
of T. cucumerina has been reported to exert the cytotoxicity
on human breast cancer cell lines [22]. Wakimoto et al. [9]
reported that cucurbitacin B exerts the anticancer activity
against ER−, Her2/neu ampliﬁed, and p53 mutant breast
cancersbothinvitroandinvivo[9].Similarly,cucurbitacinB
has been reported to inhibit Wnt signaling pathway through
reduction of Wnt-associated protein and reduced transloca-
tion of galectin-3-mediated β-catenin to the nucleus [23].
In this study, we analyzed the anticancer activity of
cucurbitacin B in human breast cancer cells lines: MCF7:5C,
MDA-MB-231, and SKBR-3 using clonogenic survival assay.
Among these three cells lines, SKBR-3 express high levels ofJournal of Oncology 5
0
102
103
104
105
0 102 103 104 105 0 102 103 104 105 0 102 103 104 105
P
I
-
A
FITC-A
0
102
103
104
105
0 102 103 104 105 0 102 103 104 105 0 102 103 104 105
P
I
-
A
FITC-A
0
102
103
104
105
0 102 103 104 105 0 102 103 104 105 0 102 103 104 105
P
I
-
A
FITC-A
0
102
103
104
105
P
I
-
A
FITC-A
0
102
103
104
105
P
I
-
A
FITC-A
0
102
103
104
105
P
I
-
A
FITC-A
0
102
103
104
105
P
I
-
A
FITC-A
0
102
103
104
105
P
I
-
A
FITC-A
0
102
103
104
105
P
I
-
A
FITC-A
0.45
94.4 1.24
3.93 2.45
52.2 14.8
30.6 0.92
46 21.6
31.4
0.46
97.4 0.59
1.55 8.96
58.7 7.82
24.6
58.7 7.82
24.6 8.96
1.4
88.8 2.33
7.51 2.53
70.1 11.5
15.9 6.57
68.1 11.1
14.2
Control 2.5 μM 5 μM
M
C
F
7
:
5
C
 
M
D
A
-
M
B
-
2
3
1
 
S
K
B
R
-
3
 
(a)
0 
10 
20 
30 
40 
50 
60 
A
p
o
p
t
o
s
i
s
 
(
%
)
 
MCF7:5C 
MDA-MB-231 
SKBR-3 
Concentration (μM)
∗∗
∗∗
∗
∗
∗
∗
Control 2.5 μM5   μM
(b)
Figure 3: Cell death of breast cancer cells induced by cucurbitacin B. MCF7:5C, MDA-MB-231, and SKBR-3 were incubated with
cucurbitacin B for 48hr and apoptosis was analyzed by staining phosphatidylserine translocation with FITC-Annexin V. Annexin V staining
is represented on the x-axis and PI staining is represented on the y-axis (a). The most representative result of three independent experiments
is shown. Simple vertical bars represent the mean apoptosis rate of all of breast cancer cells (b). Results shown are the average of three
independent experiments.
∗P < 0.05 versus nontreated control,
∗∗P < 0.01 versus nontreated control.6 Journal of Oncology
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Figure 4: Eﬀect of cucurbitacin B on p21 gene expression.
MCF7:5C, MDA-MB-231, and SKBR-3 were incubated for 48hr
with the speciﬁed concentrations of cucurbitacin B, and RNA was
extractedforreal-timePCRtoquantitatetheexpressionlevelofp21.
Relative expression levels of p21 mRNA at indicated concentration.
Results shown are the average of three independent experiments.
∗P < 0.05 versus nontreated control,
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Her2/neu receptor, whereas MCF7:5C and MDA-MB-231 do
not express these receptor. We showed that cucurbitacin B
has potent antiproliferation activity in all cell types. SKBR-
3 is the most sensitive to cucurbitacin B when compared
with other two cell lines. We further determined the eﬀect
of cucurbitacin B on cell cycle progression and apoptosis
induction in breast cancer cell lines. The results showed that
apoptotic cells were induced by cucurbitacin B treatment in
all cell lines, and cell cycle is arrested at the G2/M phase
in MCF7:5C and MDA-MB-231 cells but not in SKBR-
3 cells (Figure 2). Several authors have shown that the
radiosensitizing eﬀect of anticancer drug is due to cell cycle
alteration. Paclitaxel, a microtubule-stabilizing drug, has
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Figure 5: Eﬀect of cucurbitacin B on p21 protein expression in
breast cancer cells. (a) Cells were treated with cucurbitacin B for
48hr, and then the total proteins were extracted and performed
western blotting to analyze p21 expression. Tubulin was used as an
equal loading control. (b) Densitometric analyses of expression of
p21 relative to the untreated control.
∗P < 0.05 versus nontreated
control,
∗∗P < 0.01 versus nontreated control.
been shown to enhance radiosensitivity by blocking cells in
G2/M phase of the cell cycle [24, 25]. Since cells in the G2/M
phase have been reported to be more radiosensitive than
in other phases of cell cycle, and cucurbitacin B treatment
increases the number of cells in G2/M phase of the cell
cycle and thus enhanced the eﬀects of radiation on breast
cancer cell line. In our study, cucurbitacin B exerted the
radiosensitivity when administered 5μM of cucurbitacin
B before radiation on MCF7:5C and MDA-MB-231 cells.
However, no radiosensitization occurred when SKBR-3 cells
were exposed to cucurbitacin B at 5μM and radiation, and
no accumulation of cells in the G2/M phase was observed
prior to the start of irradiation under these conditions.
p21 and cell cycle checkpoints were shown to modulate the
nucleotide excision repair process to facilitate the repair ofJournal of Oncology 7
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Figure 6: Clonogenic survival of breast cancer cells after treatment including irradiation with or without cucurbitacin B. MCF7:5C, MDA-
MB-231, and SKBR-3 cells were treated with 5μM of cucurbitacin B for 48hr before radiation. Following the incubation period with speciﬁc
drug concentration, cells were harvested, resuspended in fresh medium, and then irradiated at 0–8Gy. Colony formation was detected by 21
days later and survival curve was constructed. Data was a summary of three experiments.
DNA damage even in the absence of wild-type p53 [26].
Our results indicate that p21 expression level by cucurbitacin
B treatment mostly showed upregulation in all cell lines
especially in SKBR-3 which showed the highest induction
when compared with other cell types (Figures 4 and 5).
Therefore, no radiosensitization was manifest using 5μM
cucurbitacin B in SKBR-3 likely because cucurbitacin B
did not induce a G2/M cell cycle arrest. Taken together,
the radiosensitizing eﬀect by cucurbitacin B was dependent
on the induction of G2/M arrest in breast cancer cells
but not necessarily on the induction of p21. In summary,
cucurbitacin B can enhance the eﬀect of radiosensitization
on breast cancer cells and studies in vivo are required to
evaluate the biological eﬃcacy of cucurbitacin B treatment.
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